Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares, rose in value, with the stock price up by 2.30% to the previous day’s close as strong demand from buyers drove the stock to $14.25.
Actively observing the price movement in the last trading, the stock closed the session at $13.93. The value of beta (5-year monthly) was 1.04. Referring to stock’s 52-week performance, its high was $14.45, and the low was $7.09. On the whole, TEVA has fluctuated by 5.32% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.52, which is expected to increase to $0.61 for fiscal year $2.4 and then to about $2.63 by fiscal year 2025. Data indicates that the EPS growth is expected to be -6.30% in 2025, while the next year’s EPS growth is forecast to be 9.60%.
Analysts have estimated the company’s revenue for the quarter at $3.76 billion, with a low estimate of $3.66 billion and a high estimate of $3.86 billion. According to the average forecast, sales growth in current quarter could jump up 3.70%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $15.82 billion, representing a decrease of -0.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TEVA’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TEVA currently trading nearly 3.60% and 8.59% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 62.84, while the 7-day volatility ratio is showing 2.44% which for the 30-day chart, stands at 2.40%. Furthermore, Teva- Pharmaceutical Industries Ltd. ADR (TEVA)’s beta value is 1.06, and its average true range (ATR) is 0.34.
A comparison of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) with its peers suggests the former has fared considerably weaker in the market. TEVA showed an intraday change of 2.30% in last session, and over the past year, it grew by 56.59%%.
Data on historical trading for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) indicates that the trading volumes over the past 10 days have averaged 8.45 million and over the past 3 months, they’ve averaged 10.73 million. According to company’s latest data on outstanding shares, there are 1.12 billion shares outstanding.
Nearly 0.01% of Teva- Pharmaceutical Industries Ltd. ADR’s shares belong to company insiders and institutional investors own 52.46% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.46 million shares as on Mar 15, 2024, resulting in a short ratio of 1.17. According to the data, the short interest in Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stood at 0.93% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 15.39 million. The stock has risen by 36.49% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TEVA stock heading into the next quarter.
